Company / Current Assets
Celldex Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$534.7M
FY2025
5-year range
$317.7M / $747.2M
FY2021-FY2025
Trend
-28.4%
vs FY2024
Sector context
#108 of 160
Health Care
What the data says
At $535M, Celldex Therapeutics, Inc.'s current assets ranks #108 of 160 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $67M in FY2019 to $747M in FY2024.
Based on SEC 10-K filings.
$535M in FY2025 with a 5-year CAGR of +22.0%.
Improved from $432M to $535M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +18.9%
- 5-Year CAGR
- +22.0%
- 10-Year CAGR
- -
Sector benchmark
#108 of 160 in Health CareTop 68% of 160This company $534.7M Sector average $5.2B
▼
-89.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.0%, indicating consistent growth.
- In FY2025, current assets decreased 28.4% year-over-year.
- Ranks #108 out of 160 companies in the Health Care sector.
- Peak current assets was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $534.7M | -28.4% |
| FY2024 | $747.2M | +73.1% |
| FY2023 | $431.7M | +35.9% |
| FY2022 | $317.7M | -22.7% |
| FY2021 | $410.8M | +107.7% |
| FY2020 | $197.8M | +196.6% |
| FY2019 | $66.7M | -32.7% |
| FY2018 | $99.1M | -31.6% |
| FY2017 | $144.8M | -26.0% |
| FY2016 | $195.6M | -33.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026